Head tilt test helps diagnose paralysis of eye muscles
July 15th 2002Editor's Note: The Bielschowsky head tilt test: all ophthalmologists learned it, few use it, fewer understand it, and most have forgotten it! In this month's column, we will cover the life and times of German ophthalmologist Alfred Bielschowsky (1871-1940), including his contributions to strabismus research.
Onset of glaucoma may be delayed with treatment of IOP
July 15th 2002Investigators from 22 clinical centers across the country have discovered that eye drops used to treat elevated IOP can be effective in delaying the onset of glaucoma, according to the recently released results of the Ocular Hypertension Treatment Study (OHTS).
Many still focus on controlling IOP, despite new definition
July 15th 2002New York-The official definition of glaucoma has changed over the years to downplay the role of IOP, although IOP does remain a central issue in the treatment and prevention of the condition. Such was the conclusion drawn from discussions at the Glaucoma 2002 meeting here.
Invest in advertising to become patients' first choice
July 15th 2002New York-Achieving success in an optical dispensary requires a continued, innovative marketing effort by the entire office staff, according to two experts who spoke on the subject at the American Association of Dispensing Ophthalmologists (AADO) 6th Dispensing Ophthalmology Conference held during this year's International Vision Expo East.
Anti-VEGF therapy holds promise for CNV in AMD
July 1st 2002Fort Lauderdale, FL-Anti-vascular endothelial growth factor (anti-VEGF) therapy is a promising treatment of neovascularization brought on by various ocular diseases, including age-related macular degeneration (AMD), according to Lawrence J. Singerman, MD.
Intravitreal triamcinolone for AMD appears promising, but more studies needed
July 1st 2002Fort Lauderdale, FL-Intravitreal triamcinolone appears to inhibit the growth of choroidal neovascularization (CNV) and reduce subretinal fluid in the short term, but it needs further evaluation, ac-cording to Mark Gillies, MB, BS, PhD.
AREDS supports the use of nutritional supplements for AMD
July 1st 2002Fort Lauderdale, FL-Of the nearly 60 million people in the United States over age 55, 8 million are estimated to be at high risk for advanced age-related macular degeneration (AMD), making it an important public health concern. However, nutritional supplements may be helpful to reduce this risk, according to the Age-Related Eye Disease Study (AREDS).
Obstructive sleep apnea worsens diabetic retinopathy
July 1st 2002Philadelphia-Obstructive sleep apnea appears to be a significant, previously unrecognized aggravating factor in diabetic retinopathy that promotes progression of ischemia and edema, according to Stephen Sinclair, MD, clinical professor, Hahnemann University Hospital, Philadelphia.
New test helps patients self-monitor for AMD lesions
July 1st 2002Tel Aviv, Israel-The macular computerized psychophysical test (MCPT)-a new test for monitoring patients with age-related macular degeneration (AMD)-seems to be an efficient method for self-detection of AMD-related lesions, according to Anat Loewenstein, MD.
NSAIDs may interfere with glaucoma medication
July 1st 2002San Antonio, TX-Before prescribing one of the newer medications for glaucoma, clinicians should ask what drugs the patient may be taking for aches and pains-especially non-steroidal anti-inflammatory agents (NSAIDs), including something as innocuous as aspirin, said William E. Sponsel, MD.
Upgrades offer vitreoretinal surgeons increased control and efficiency
July 1st 2002Vitreoretinal surgeons are benefiting from upgrades to the Accurus Surgical System (Alcon Laboratories). The new model features fourth-generation software (XS4), dual dynamic drive (3D) technology that maximizes efficiency, and advanced vitrectomy probes offering increased cutting speeds for exquisite control.
Softer sell on deck for prescription drugs
July 1st 2002As of July 1, a new marketing code adopted by the Pharmaceutical Research and Manufacturers of America (PhRMA) takes effect. The code would put an end to gifts and dinners for doctors and their staffs, and even cash giveaways, in addition to all forms of recompense that have nothing to do with patient education.
Modified steroid has 'potential' for treating subfoveal CNV in AMD
July 1st 2002Fort Lauderdale, FL-Anecortave acetate (Alcon), a chemically modified steroid, acts in a unique way to suppress abnormal blood vessel growth in patients with subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
Various options available for correcting induced hyperopia
June 15th 2002Boston-The incidence of overcorrection following PRK and LASIK is fortunately very small, generally less than 5%. Unfortunately, the incidence of consecutive hyperopia after RK is significantly greater and, over time, becomes higher with a hyperopic shift, said Helen K. Wu, MD.
Soft tissue fillers provide patients with more options
June 15th 2002The search for an ideal soft tissue filler to cor-rect various facial folds and wrinkles has gone on for years. At the turn of the last century, injectable paraffin was tried but quickly found to be unacceptable.1 A refined form of liquid silicone was introduced in the 1960s, and for the next 30 years, various forms of injectable silicone were used with few reported complications. Unfortunately, numerous complications arose from the use of adulterated or impure silicones and as a result, injectable silicones were abandoned.2
Get to know various lens products, fabrication technologies
June 15th 2002New York-Short of performing a careful refraction, one of the most significant improvements you can make in your patients' glasses is to prescribe an anti-reflective (AR) coating for their lenses, according to a New York ophthalmologist and a Texas optician.
Congenital ptosis is more than just a droopy eyelid
June 1st 2002Visual development and cosmesis are important considerations in the management of congenital ptosis. While parents often are concerned about the child's appearance, the ophthalmologist's role is to make sure the patient's vision is appropriately assessed and to educate the parents regarding the potential relationship between ptosis and visual development.
Postop ION: Increasing awareness or increasing incidence?
June 1st 2002Visual loss following non-ocular surgical procedures is becoming increasingly recognized and reported in the literature by anesthesiologists, surgeons, and ophthalmologists. The usual cause for visual loss in these cases is ischemic optic neuropathy (ION).
Molecule engineered to target neovascularization in AMD
June 1st 2002A genetically engineered molecule designed to kill cancers by destroying their rapidly growing blood vessels offers a new line of attack against age-related macular degeneration (AMD) and other retinal conditions, said Alan Garen, PhD.
Fluorescein angiography indicated in patients with AIDS
June 1st 2002Editor's Note: In the absence of other identifiable causes, vision loss in HIV patients may be due to ischemic maculopathy, and that diagnosis should be investigated with fluorescein angiography. The clinical and angiographic features of five patients with HIV infection-related ischemic maculopathy were described in a paper recently published by Emmett T. Cunningham Jr., MD, PhD, MPH, and associates in the American Journal of Ophthalmology. In this new Ophthalmology Times column, Dr. Cunningham reviews the characteristic features of those patients and highlights the importance of considering a fluorescein angiogram in the diagnostic evaluation of HIV-positive patients with unexplained vision loss.